Impact Factor
4.37
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
7.11
10,530 total citations
h5-index
121
h5 depth signal
Cited share
66.3%
1,023 of 1,543
Total citations
10,530
Citation footprint
Metric signal
3.29
External metric anchor
Self-citation
1.9%
202 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
8,260
United Kingdom
1,131
China
1,053
Canada
958
Germany
871
Citing Fields of Research
Oncology
4,980
Breast Cancer
4,715
Immunology
3,189
Cancer & Development
1,915
Lung Cancer
1,514
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
26,884
Articles tracked across the journal lifetime
Indexed publication set
1,543
1,023 cited publications
Last 12 months
2,806
233.8 publications/month
Open access share
12.0%
338 OA publications in the last year
Leading citing country
United States
8,260 citing publications
Leading citing field
Oncology
4,980 citing publications
Latest tracked publication
19 October 2026
10 recent records available
Coverage & Indexing History
v2n1,Jan. 1965-
v2n1,Jan. 1965-
Active Coverage
Research Focus & Classification
Indexed Subjects
Breast Cancer
Issuing & Sponsoring Bodies
Contributor
American Association for Cancer Research
Broad Categories
Neoplasms
Lung Cancer
Immunology
Urology
Musculoskeletal & Nerve Cancer
Prostate Cancer
Lymphomas
MeSH Descriptors
Neoplasms
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1158/1078-0432.ccr-26-2916
Open DOI
When the Tumor Disappears, Must the Larynx Follow?
REMATCH, a single-institution phase II study, evaluated reduced-volume surgery in patients with locally advanced head and neck cancer responding to neoadjuvant immunochemotherapy. Two-year disease-free survival was 90%, with universal la...
02
DOI 10.1158/1078-0432.ccr-26-1824
Open DOI
Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcinoma: a multicenter, single-arm, phase II trial
Purpose: The prognosis for metastatic pancreatic ductal adenocarcinoma (mPDAC) remains dismal. In this multicenter, single-arm, phase II study, we evaluated the combination of serplulimab, gemcitabine plus nab-paclitaxel, and radiotherap...
03
DOI 10.1158/1078-0432.ccr-26-2049
Open DOI
Anti-TNFR2 antibody BI-1808 induces tumor regression and antitumor T cell immunity through T reg and myeloid cell modulation in patients with solid tumors
Purpose: To clinically evaluate the safety, pharmacodynamic biomarkers, and efficacy of BI-1808, a first-in-class ligand-blocking, Fcγ receptor-engaging anti-TNFR2 antibody, as a novel immunotherapy approach to enhance antitumor immunity...
04
05
DOI 10.1158/1078-0432.ccr-26-3222
Open DOI
Editor’s Note: ERK Regulates HIF1α-Mediated Platinum Resistance by Directly Targeting PHD2 in Ovarian Cancer
06
DOI 10.1158/1078-0432.ccr-26-2942
Open DOI
Second- and third-line outcomes after selective RET inhibitor failure in RET fusion-positive metastatic lung cancer: A real-world analysis from the RET-MAP registry
Purpose: Selective RET inhibitors (SRIs) are the first-line standard for RET fusion-positive NSCLC, but no treatment is established after progression. Real-world outcomes are needed to inform trial design and contextualize single-arm stu...
07
DOI 10.1158/1078-0432.ccr-26-2052
Open DOI
Multi-institutional study evaluating the role of liquid biopsy to determine risk of extraocular disease, therapy response and recurrence in retinoblastoma
Background: We analyzed whether changes in RB1 circulating tumor DNA (ctDNA) variant allele frequency (VAF) in plasma and/or cerebrospinal fluid (CSF) was associated with clinical outcomes in patients with retinoblastoma (RB). Methods: W...
08
DOI 10.1158/1078-0432.ccr-26-2212
Open DOI
DNA-Based Biomarkers as Predictors of Carboplatin Response in Neoadjuvant Treatment for Hormone Receptor Positive and Triple-Negative Breast Cancer
Purpose: This prospective, randomized neoadjuvant study evaluated DNA-based biomarkers to identify breast cancer patients most likely to benefit from carboplatin (Cb). While Cb improves outcomes in triple-negative breast cancer (TNBC), r...
09
DOI 10.1158/1078-0432.ccr-26-1008
Open DOI
Developing Effective, Evidence-Based Training for Cancer Team Science Leadership for National Impact
A 2025 National Academies’ report, The Science and Practice of Team Science, identified critical gaps in leadership development and highlighted evidence-based best practices and infrastructure needs to enhance team science. This brief pe...
10
DOI 10.1158/1078-0432.ccr-26-1720
Open DOI
Target Antigen Identification for Antibody–Drug Conjugate Therapy in Biliary Tract Cancer
Purpose: Data on antibody–drug conjugates (ADC) target expression prevalence, intertumoral heterogeneity, and genomic concordance, and its effect on clinical outcomes is limited in biliary tract cancers. Experimental Design: Resected pri...
Bibliographical & Catalog Notes
Title from cover.
Print issues ceased with v. 26, no. 24 (Dec. 2020).
Also issued online.
Vol. 1, no. 1 (JAN 1995)19980320 Notice published Printed on acid-free paper